Boardroom Alpha
Boardroom Alpha
PYXS · Additional Proxy Materials (DEFA14A) · Filed April 30, 2026

Pyxis Oncology Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 30, 2026
Ticker
PYXS
Accession
0001193125-26-194051
Boardroom Alpha · Filing insights

Pyxis Oncology board urges vote FOR Proposals 1 and 2: director slate and EY audit ratification.

About Pyxis Oncology Inc
Market cap
$108M
1Y TSR
+67.2%
3Y TSR
−11.0%
Board grade
C-
Sector
Healthcare
CEO
Thomas Civik
Last annual meeting: Jun 15, 2026 · View full Pyxis Oncology Inc profile →
DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant 

 

 

Filed by a Party other than the Registrant 

Check the appropriate box:

5 

 

 

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material under § 240.14a-12

 

PYXIS ONCOLOGY, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

 

No fee required.

 

 

Fee paid previously with preliminary materials.

 

 

Fee computed on table in exhibit required per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 


img53096847_0.jpg


PYXIS ONCOLOGY P.O. Box 8016, CARY, NC 27512-9903 YOUR VOTE MATTERS! Scan QR for digital voting Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 11, 2024 For stockholders of record as of April 18, 2024 To order paper materials, use one of the following methods. INTERNET: www.investorelections.com/ Call 1-866-648-8133 paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Pyxis Oncology, Inc. Annual Meeting of Stockholders Tuesday, June 11, 2024 10:00 AM, Eastern Time Annual Meeting to be held live via the internet - please visit at www.proxydocs.com/PYXS for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/PYXS For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/PYXS To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 31, 2024. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved

 

img53096847_1.jpg

THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 Pyxis Oncology, Inc. Annual Meeting of Stockholders 1. The election of one Class I director and three Class III directors named in the proxy statement 1.01 Santhosh Palani, Ph.D., CFA 1.02 John Flavin 1.03 Lara Sullivan,M.D. 1.04 Jakob Dupont,M.D. 2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2024 NOTE: The transaction of such other business as may properly come before the meeting, or any adjournment or postponement thereof.


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Pyxis Oncology Inc (PYXS)

Reference

Frequently asked questions

When did Pyxis Oncology Inc file this DEFA14A?
Pyxis Oncology Inc (PYXS) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 30, 2026. The accession number assigned by EDGAR is 0001193125-26-194051.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Pyxis Oncology board urges vote FOR Proposals 1 and 2: director slate and EY audit ratification. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Pyxis Oncology Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Pyxis Oncology Inc has filed under CIK 1782223, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer